Back to IRWDView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Irritable Bowel Syndrome With Constipation
View Full LandscapeDrug Information
Target Indication
Irritable Bowel Syndrome With Constipation
Clinical Trial
NCT00460811Last updated: 12/4/2025
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA11/26/2012
Constella
Constella is indicated for the symptomatic treatment of moderate to severe irritable-bowel syndrome with constipation (IBS-C) in adults.
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
Linaclotide 145 microgramsPhase 3
Opioid-Induced Constipation
Linaclotide 290 microgramsPhase 3
Irritable Bowel Syndrome Characterized by Constipation
IW-3718Phase 3
Gastroesophageal Reflux Disease (GERD)
LinaclotidePhase 3
Irritable Bowel Syndrome With Constipation
PPIPhase 2
Gastroesophageal Reflux Disease
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts